AACR logo

More articles from Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts

Abstract C066: BT5528, a Bicycle Toxin Conjugate targeting EphA2: mechanism of action and clinical translation
Gavin Bennett, Amy Brown, Gemma Mudd, Johanna Lahdenranta, Nicholas Keen

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C066; DOI: 10.1158/1535-7163.TARG-19-C066
Abstract C068: Toward precision medicine for platinums
Jennifer E Koblinski, Erica J Peterson, James D. Hampton, J Chuck Harrell, Nicholas P Farrell

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C068; DOI: 10.1158/1535-7163.TARG-19-C068
Abstract C064: The investigational peptide drug ALRN-6924, a dual inhibitor of MDMX and MDM2, is an effective myelopreservation agent
Luis A Carvajal, David Sutton, Mariam Mounir, Joseph McClanaghan, Vincent Guerlavais, Manuel Aivado, Vojislav Vukovic, Allen Annis

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C064; DOI: 10.1158/1535-7163.TARG-19-C064
Abstract C065: Dietary deprivation of non-essential amino acids improves anti-PD-1 immunotherapy in murine colon cancer
Zehui Li, Grace Yang, Shuang Zhou, Xin Wang, Xiyan Li

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C065; DOI: 10.1158/1535-7163.TARG-19-C065
Abstract LB-C09: The KRAS^G12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model
David M Briere, Andrew Calinisan, Ruth Aranda, Niranjan Sudhakar, Lauren Hargis, Sole Gatto, Julio Fernandez-Banet, Adam Pavlicek, Lars D Engstrom, Jill Hallin, James G Christensen, Peter Olson

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) LB-C09; DOI: 10.1158/1535-7163.TARG-19-LB-C09
Abstract C067: Mechanistic study of the superior anti-cancer properties of a first-in-class small molecule targeting PCNA
Long Gu, Min Li, Robert Lingeman, Robert J Hickey, Yilun Liu, Linda H Malkas

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C067; DOI: 10.1158/1535-7163.TARG-19-C067
Abstract LB-C10: Preclinical synergistic anti-tumor effect against multiple cancer types by EZH2 inhibitor EPZ-6438 plus imipridone ONC201 to mimic H3K27M mutation observed in DIPG tumors that respond to ONC201 in the clinic
Yiqun Zhang, Lanlan Zhou, Shengliang Zhang, Robyn Borsuk, Howard P. Safran, Attila A. Seyhan, Wafik S. El-Deiry

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) LB-C10; DOI: 10.1158/1535-7163.TARG-19-LB-C10
Abstract C069: The identification of MRTX849, a novel KRAS^G12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers
James G Christensen, Jay B Fell, Jill Hallin, Brian Baer, Lars engstrom, James Blake, David Briere, Josh Ballard, Michael Burkhard, John Fischer, Guy Vigers, Ruth Aranda, Vickie Bowcut, Andrew Calinisan, Lauren Hargis, Niranjan Sudhakar, Matt Marx, Peter Olson

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C069; DOI: 10.1158/1535-7163.TARG-19-C069
Abstract C070: CLR 180099, a lipid raft targeted phospholipid-drug conjugate, shows potent improved safety and efficacy against colorectal tumors
Jarrod Longcor, Anatoly Pinchuk, Randall Hoover, John Friend

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C070; DOI: 10.1158/1535-7163.TARG-19-C070
Abstract C063: A novel Nrf2 inhibitor suppresses proliferation and enhances the sensitivity of cancer cells to chemotherapy
Di Zhang, Kelly Aldrich, Thomas Dexheimer, Edmund Ellsworth, Aaron Odom, Karen Liby

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C063; DOI: 10.1158/1535-7163.TARG-19-C063

Main menu

User menu

Search

More articles from Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts

Pages

Articles

Info for

About MCT